PRECLINICAL MEDICATIONS SCREENING FOR GENETIC MODELS OF ALCOHOLISM

酗酒遗传模型的临床前药物筛选

• 批准号: 8948166
• 负责人: RICHARD L. BELL, PH.D.
• 金额: $ 35.46万
• 依托单位: TRUSTEES OF INDIANA UNIVERSITY
• 依托单位国家: 美国
• 财政年份: 2014
• 资助国家: 美国
• 起止时间: 2014-09-29 至 2019-09-28
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/8948166
• 关键词: Address; Alcohol consumption; Alcohol dependence; Alcoholism; Alcohols; Behavior; Breeding; Contracts; Data; Data Display; Development; Drug Industry; Future; Genetic Models; Human Resources; Intellectual Property; Modeling; National Institute on Alcohol Abuse and Alcoholism; Neurosciences; Pharmaceutical Preparations; Program Development; Provider; Rattus; Reporting; Testing; Work; blind; clinical toxicology; efficacy testing; interest; pre-clinical; preference; programs; screening

This contract is to address the present and anticipated future needs of NIAAA’s Medication Development Program of the Division of Neuroscience and Behavior’s Preclinical Medication Efficacy Testing Program. This replacement contract will continue the blind testing of reference compounds and proprietary compounds in P rats and HAD1 rats selectively bred for alcohol preference. The contract will use mechanisms having intellectual property conditions favorable to compound providers. This will eliminate a major barrier to testing optimized compounds having preclinical as well as clinical toxicology data and will stimulate interest by the pharmaceutical industry in developing high quality, marketable compounds for alcoholism. The statement of work requirements are considered to be severable.

该合同旨在满足NIAAA神经科学和行为临床前药物疗效测试计划的当前和预期的未来需求。该替代合同将继续对P大鼠的参考化合物和专有化合物进行盲目测试，并有1只大鼠选择性地育出了酒精偏爱。该合同将使用具有有利于复合提供商的知识产权条件的机制。这将消除测试具有临床前和临床毒理学数据的优化化合物的主要障碍，并将激发制药行业对开发高质量，可销售的酒精中毒化合物的兴趣。工作要求声明被认为是可分裂的。